Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Halts Avastin Trial Enrollment Due To GI Perforations

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase II study of bevacizumab in platinum-refractory ovarian cancer patients demonstrated a higher rate of GI perforations than previously seen in studies of the oncologic.

You may also be interested in...



Genentech Avastin Label Adds Third-Line Data Showing Minimal Efficacy

NCI study of bevacizumab demonstrated a 1% response rate in refractory metastatic colorectal cancer when combined with 5-FU/LV.

Genentech Avastin Label Adds Third-Line Data Showing Minimal Efficacy

NCI study of bevacizumab demonstrated a 1% response rate in refractory metastatic colorectal cancer when combined with 5-FU/LV.

Avastin Lung Cancer Reimbursement Will Be Case By Case, Genentech Says

The company says it is too early to determine the extent of off-label use of Avastin in lung cancer. Genentech will present data on use of Avastin alone, as well as in combination with Tarceva, for the treatment of lung cancer at ASCO's annual meeting in May.

Related Content

Topics

UsernamePublicRestriction

Register

PS062942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel